Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
September 13, 2024 06:45 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent” or the “Company”) today announced that it has entered into an agreement to resolve the...
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
September 12, 2024 08:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract modification executing an option period by the Biomedical...
$12.5 Bn Influenza Vaccine Market to 2032 by Vaccine Type, Technology, Age Group, Route of Administration, and Region
September 09, 2024 10:00 ET
|
Research and Markets
Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "Influenza Vaccine Market Report by Vaccine Type, Technology, Age Group, Route of Administration, and Region 2024-2032" report has been added to ...
OHA is Administrative Agent and Sole Lender for Emergent BioSolutions Debt Refinancing
September 04, 2024 17:51 ET
|
Oak Hill Advisors, LP
New York, New York, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oak Hill Advisors (“OHA”) served as Administrative Agent and sole lender of a $250 million term loan facility supporting Emergent BioSolutions...
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
September 04, 2024 08:00 ET
|
Milestone Pharmaceuticals Inc.
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of...
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
September 03, 2024 07:08 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the closing of a new credit facility agreement with Oak Hill Advisors for a term loan of...
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
August 30, 2024 08:16 ET
|
Emergent BioSolutions
For the second year, Emergent is teaming up with pro football legend, Emmitt Smith, to educate communities on opioid risks and how to be prepared with NARCAN® Nasal SprayIn recognition of...
Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
August 29, 2024 18:53 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics...
Novonesis delivers strong half-year results and increases full-year outlook
August 27, 2024 10:34 ET
|
Novozymes A/S
In the first half of 2024, Novonesis delivered 7% organic sales growth with an adjusted EBITDA margin at 35.3%. Following strong first half-year performance, Novonesis increases its full-year organic...
Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
August 20, 2024 11:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has completed the sale of its drug product facility in Baltimore-Camden to an affiliate...